Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 276

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 276
---
excluding the United States, Japan and South Korea). Cara retained full development and commercialization rights for KORSUVA injection for the treatment of CKD-aP in dialysis patients in the United States except in the dialysis clinics of Fresenius Medical Care North America (“FMCN”), where VFMCRP promotes KORSUVA injection under a profit-sharing arrangement.

Cara was eligible to receive from CSL Vifor commercial milestone payments in the aggregate of up to $440.0 million, all of which milestones were sales related. Cara was also eligible to receive tiered double-digit royalty payments based on annual net sales, as defined, of KORSUVA (difelikefalin) injection in the licensed territories. In the United States, CSL Vifor promoted KORSUVA (difelikefalin) injection in the

<div align='center'>169</div>

TABLE OF CONTENTS

dialysis clinics of FMCNA under a profit-sharing arrangement (subject to the terms and conditions of the Fresenius Agreement) based on net FMCNA clinic sales (as defined in Fresenius Agreement) and Vifor Fresenius Medical Care Renal Pharma Ltd. was entitled to 50% of such net profits, subject to potential adjustments in a calendar year based on certain conditions.

In January 2023, VFMCRP and Winhealth Pharma signed a long-term exclusive licensing agreement for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China.

Vifor Fresenius Medical Care Renal Pharma Ltd. paid Cara $0 and $414,885 pursuant to the Fresenius Agreement for the fiscal years ended December 31, 2024 and 2023, respectively. In addition, no amounts were paid to Cara pursuant to the Fresenius Agreement. In addition, no amounts were paid to Cara pursuant to the Fresenius Agreement following the fiscal year ended December 31, 2024 through the date the agreement was terminated.

The Fresenius Agreement was terminated upon consummation of the Asset Disposition.

#### Fresenius Supply Agreement
In connection with Fresenius Agreement, Cara also had a related supply agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. (the “Fresenius Supply Agreement”), pursuant to which Cara retained the right to make and have made KORSUVA (difelikefalin)